Literature DB >> 12575968

Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study.

C Noel Bairey Merz1, B Delia Johnson, Barry L Sharaf, Vera Bittner, Sarah L Berga, Glenn D Braunstein, T Keta Hodgson, Karen A Matthews, Carl J Pepine, Steven E Reis, Nathaniel Reichek, William J Rogers, Gerald M Pohost, Sheryl F Kelsey, George Sopko.   

Abstract

OBJECTIVES: We sought to evaluate hypoestrogenemia of hypothalamic origin and its association with angiographic coronary artery disease (CAD) in premenopausal women.
BACKGROUND: Coronary artery disease in premenopausal women appears to have a particularly poor prognosis. Primate animal data suggest that premenopausal CAD is strongly determined by psychosocial stress-induced central disruption of ovulatory cycling and resulting hypoestrogenemia.
METHODS: We assessed reproductive hormone blood levels and angiographic CAD using core laboratories in 95 premenopausal women with coronary risk factors who were enrolled in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation and were undergoing coronary angiography for evaluation for suspected ischemia.
RESULTS: Premenopausal women with angiographic CAD (n = 13) had significantly lower estradiol, bioavailable estradiol, and follicle-stimulating hormone (FSH) (all p < 0.05) than women without angiographic CAD (n = 82), even after controlling for age. Hypoestrogenemia of hypothalamic origin, defined as estradiol <184 pmol/l (50 pg/ml), FSH <10 IU/l, and luteinizing hormone <10 IU/l, was significantly more prevalent among the women with CAD than those without CAD (9/13 [69%] vs. 24/82 [29%], respectively, p = 0.01). Hypoestrogenemia of hypothalamic origin was the most powerful predictor of angiographic CAD in a multivariate model (odds ratio [OR] 7.4 [confidence interval (CI) 1.7 to 33.3], p = 0.008). Anxiolytic/sedative/hypnotic and antidepressant medication use were independent predictors of hypoestrogenemia of hypothalamic origin in a multivariate model (OR 4.6 [CI 1.3 to 15.7], p = 0.02, OR 0.10 [CI 0.01 to 0.92], p = 0.04, respectively).
CONCLUSIONS: Among premenopausal women undergoing coronary angiography for suspected myocardial ischemia, disruption of ovulatory cycling characterized by hypoestrogenemia of hypothalamic origin appears to be associated with angiographic CAD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12575968     DOI: 10.1016/s0735-1097(02)02763-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  68 in total

1.  The relationship of menopausal status and rapid menopausal transition with carotid intima-media thickness progression in women: a report from the Los Angeles Atherosclerosis Study.

Authors:  B Delia Johnson; Kathleen M Dwyer; Frank Z Stanczyk; Vera Bittner; Sarah L Berga; Glenn D Braunstein; Ricardo Azziz; YuChing Yang; Georgina E Hale; C Noel Bairey Merz
Journal:  J Clin Endocrinol Metab       Date:  2010-06-16       Impact factor: 5.958

2.  Proceedings from the scientific symposium: Sex differences in cardiovascular disease and implications for therapies.

Authors:  C Noel Bairey Merz; Saralyn Mark; Barbara D Boyan; Alice K Jacobs; Prediman K Shah; Leslee J Shaw; Doris Taylor; Eduardo Marbán
Journal:  J Womens Health (Larchmt)       Date:  2010-06       Impact factor: 2.681

3.  Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.

Authors:  Wulf H Utian; David F Archer; Gloria A Bachmann; Christopher Gallagher; Francine n Grodstein; Julia R Heiman; Victor W Henderson; Howard N Hodis; Richard H Karas; Rogerio A Lobo; JoAnn E Manson; Robert L Reid; Peter J Schmidt; Cynthia A Stuenkel
Journal:  Menopause       Date:  2008 Jul-Aug       Impact factor: 2.953

4.  Sex Differences in Outcomes Following Percutaneous Coronary Intervention According to Age.

Authors:  Kelly C Epps; Elizabeth M Holper; Faith Selzer; Helen A Vlachos; Sarah K Gualano; J Dawn Abbott; Alice K Jacobs; Oscar C Marroquin; Srihari S Naidu; Peter W Groeneveld; Robert L Wilensky
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-02

Review 5.  Hormone replacement therapy and heart disease: the remains of the oestrogen hypothesis.

Authors:  A H E M Maas; Y T van der Schouw; D E Grobbee; Y van der Graaf
Journal:  Neth Heart J       Date:  2003-11       Impact factor: 2.380

6.  Trajectories of estradiol and follicle-stimulating hormone over the menopause transition and early markers of atherosclerosis after menopause.

Authors:  Samar R El Khoudary; Nanette Santoro; Hsiang-Yu Chen; Ping G Tepper; Maria M Brooks; Rebecca C Thurston; Imke Janssen; Sioban D Harlow; Emma Barinas-Mitchell; Faith Selzer; Carol A Derby; Elizabeth A Jackson; Daniel McConnell; Karen A Matthews
Journal:  Eur J Prev Cardiol       Date:  2015-09-18       Impact factor: 7.804

Review 7.  Contraceptive hormone use and cardiovascular disease.

Authors:  Chrisandra L Shufelt; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2009-01-20       Impact factor: 24.094

Review 8.  Gender and anti-thrombotic therapy: from biology to clinical implications.

Authors:  Rossella Marcucci; Gabriele Cioni; Betti Giusti; Cinzia Fatini; Lorenza Rossi; Maddalena Pazzi; Rosanna Abbate
Journal:  J Cardiovasc Transl Res       Date:  2014-01-28       Impact factor: 4.132

Review 9.  Women and ischemic heart disease: evolving knowledge.

Authors:  Leslee J Shaw; Raffaelle Bugiardini; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2009-10-20       Impact factor: 24.094

10.  Reproductive history and hormonal birth control use are associated with coronary calcium progression in women with type 1 diabetes mellitus.

Authors:  Janet K Snell-Bergeon; Dana Dabelea; Lorraine G Ogden; John E Hokanson; Gregory L Kinney; James Ehrlich; Marian Rewers
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.